Regeneron's Combination with Novo Nordisk's Semaglutide Cuts Muscle Loss by Half
nashnova research
Regeneron's investigational drug trevogrumab, combined with semaglutide, cut muscle loss by 50% during weight loss — the first clinical-grade fix for GLP-1 drugs' biggest side-effect problem.
Why do weight-loss drugs burn muscle too?
GLP-1 drugs — a class that mimics gut hormones to suppress appetite — drive rapid weight loss, but roughly 30% of the weight lost is lean muscle, not fat.
This means → users aren't just shedding fat; they're losing the strength and metabolic foundation their bodies run on.
Regeneron executive Boaz Hirshberg confirmed that ratio at the European Association for the Study of Diabetes annual meeting and said trevogrumab can block this process.
How much muscle did the combo preserve?
The trial enrolled nearly 1,000 obese patients aged 18–65. The semaglutide-only group lost 6.7% of lean body mass over 26 weeks; the 75 mg trevogrumab combo group lost just 3.3% — roughly half.
MRI scans of the thigh showed the 75 mg group retained over 70% of the muscle that would otherwise have been lost at 52 weeks.
A critical finding: after patients stopped semaglutide but kept taking trevogrumab, muscle mass recovered to pre-trial levels. In plain terms = the drug doesn't just defend muscle — it may help rebuild what was already lost.
Why was the triple combo scrapped?
The trial originally added a second Regeneron antibody, garetosmab. In the first 26 weeks, two participants died on higher-dose triple therapy — one from an unknown cause with multiple cardiovascular risk factors, one from cardiac arrest with a cardiac history.
The triple combo preserved more muscle than the dual, but carried higher adverse-event rates, including muscle spasms. Regeneron said it will not advance the triple regimen.
This reflects a common clinical-development trade-off: stronger combinations often narrow the safety window, and regulators and markets both favor risk-controlled profiles.
What comes next for the 75 mg regimen?
Regeneron has selected 75 mg once weekly as the go-forward dose. Trevogrumab monotherapy's safety profile tracked close to semaglutide's, with no unexpected adverse events.
The company plans a new mid-stage trial in patients over 65. This means → Regeneron is targeting the population where muscle loss matters most — older obese patients face higher muscle-wasting risk during weight loss and have the most urgent clinical need.
How big is this race, and who's in it?
At least a dozen companies are developing muscle-preservation therapies. Analysts project the category could reach $30 billion in annual sales by 2035.
Trevogrumab is a myostatin inhibitor — a drug that releases the "brake" on muscle growth — with a mechanism entirely different from GLP-1s, meaning it could theoretically pair with multiple weight-loss drugs.
In plain terms = GLP-1s solved "how to lose weight"; trevogrumab and its peers are trying to solve "how to lose weight without losing muscle too." Whether Phase 3 data at scale can replicate these mid-stage results is the milestone the market will price on.
市场有风险，内容仅供研究参考，不构成投资建议。